1. Introduction {#sec1-cancers-12-00693}
===============

Chromosomal rearrangements are an important class of driver oncogene alterations in non-small cell lung cancer (NSCLC). Validated examples of oncogenic fusion drivers in NSCLC include anaplastic lymphoma kinase (*ALK*) and *ROS1* gene fusions \[[@B1-cancers-12-00693],[@B2-cancers-12-00693],[@B3-cancers-12-00693],[@B4-cancers-12-00693]\]. Advanced NSCLC harboring either *ALK* or *ROS1* fusion can be effectively treated with tyrosine kinase inhibitors (TKIs) targeting *ALK* or *ROS1*, respectively, and several *ALK*/*ROS1* tyrosine kinase inhibitors (TKIs) are now approved by the United States Food and Drug Administration.

Fusions involving the rearranged during transfection proto-oncogene (*RET*) occur in 1--2% of NSCLC \[[@B5-cancers-12-00693],[@B6-cancers-12-00693],[@B7-cancers-12-00693]\], and are more commonly seen in patients with minimal to no smoking history and adenocarcinoma histologic subtype, reminiscent of *ALK* and *ROS1* fusions \[[@B8-cancers-12-00693],[@B9-cancers-12-00693],[@B10-cancers-12-00693],[@B11-cancers-12-00693]\]. *RET* fusions are mutually exclusive with other oncogenic drivers such as *ALK* and *ROS1* fusions. Until recently, *RET*-selective TKIs were not available, and multitargeted TKIs with anti-*RET* activity such as cabozantinib and vandetanib were therefore tested in patients with advanced *RET* fusion-positive (*RET*+) NSCLC, with modest activity and significant toxicities \[[@B12-cancers-12-00693],[@B13-cancers-12-00693],[@B14-cancers-12-00693],[@B15-cancers-12-00693],[@B16-cancers-12-00693],[@B17-cancers-12-00693],[@B18-cancers-12-00693],[@B19-cancers-12-00693],[@B20-cancers-12-00693],[@B21-cancers-12-00693]\]. More recently, two highly potent, *RET*-selective TKIs, BLU-667 and LOXO-292, have entered the clinic ([ClinicalTrials.gov](ClinicalTrials.gov) identifier NCT03037385 and NCT03157128, respectively). Both of these agents have demonstrated promising preliminary safety and efficacy profiles in patients with advanced solid tumors harboring *RET* alterations, including *RET*+ NSCLC \[[@B15-cancers-12-00693],[@B22-cancers-12-00693],[@B23-cancers-12-00693],[@B24-cancers-12-00693],[@B25-cancers-12-00693]\].

Prior studies have suggested distinct imaging features that may be seen in NSCLCs harboring specific driver mutations, including *ALK* and *ROS1* fusions \[[@B26-cancers-12-00693],[@B27-cancers-12-00693],[@B28-cancers-12-00693],[@B29-cancers-12-00693],[@B30-cancers-12-00693],[@B31-cancers-12-00693],[@B32-cancers-12-00693],[@B33-cancers-12-00693],[@B34-cancers-12-00693],[@B35-cancers-12-00693]\]. Less is known, however, regarding the radiologic features of advanced *RET*+ NSCLC. Here, we performed a retrospective analysis to determine the imaging features and metastatic patterns of advanced *RET+* NSCLC, specifically as compared to those of *ALK*+ and *ROS1*+ NSCLC, the most common oncogenic fusions in lung cancer.

2. Results {#sec2-cancers-12-00693}
==========

2.1. Patient Characteristics {#sec2dot1-cancers-12-00693}
----------------------------

The study included 215 patients with advanced NSCLC harboring either *RET*, *ALK*, or *ROS1* gene fusions (*RET*: 32; *ALK*: 116; *ROS1*: 67). Baseline characteristics of these patients are summarized in [Table 1](#cancers-12-00693-t001){ref-type="table"}. Patients with *RET+* NSCLC were older at initial diagnosis compared to those with *ALK+* or *ROS1+* NSCLC (median age: *RET*: 64 years vs *ALK*: 51 years, *p* \< 0.001; vs *ROS1*: 54 years, *p* = 0.042). While the majority of tumors in all three molecular subgroups had adenocarcinoma histology, there was a higher frequency of neuroendocrine histology among *RET+* tumors included in this study (*RET*: 12% vs *ALK*: 2%, *p* = 0.025; vs *ROS1*: 0%, *p* = 0.010). A higher proportion of *RET*+ patients in this cohort presented initially with stage I-II disease (*RET*: 25% vs *ALK*: 6%, *p* = 0.004; vs *ROS1*: 7%, *p* = 0.023).

2.2. Imaging Features of the Primary Tumor {#sec2dot2-cancers-12-00693}
------------------------------------------

We first evaluated the radiologic features of the primary tumor in *RET*+ NSCLC compared to *ALK*+ or *ROS1*+ NSCLC. *RET+* primary tumors were more likely to be peripheral in location compared to *ALK*+ and *ROS1+* tumors (*RET*: 69% vs *ALK*: 47%, *p* = 0.029; vs *ROS1*: 36%, *p* = 0.003). Otherwise, no significant differences were observed among the three groups with respect to primary tumor size, density, or lobar location ([Table 2](#cancers-12-00693-t002){ref-type="table"}). A vast majority of the primary tumors were solid in density. Air bronchograms, cavities, and calcifications were infrequently observed in all three subgroups without a significant difference.

2.3. Patterns of Metastases {#sec2dot3-cancers-12-00693}
---------------------------

We next compared patterns of metastases at initial diagnosis as validated by radiologic imaging among the three gene fusion groups, as summarized in [Table 3](#cancers-12-00693-t003){ref-type="table"}. A higher frequency of brain metastasis was noted at initial diagnosis in *RET+* NSCLC compared to *ROS1+* NSCLC (*RET*: 32% vs *ROS1*: 10%; *p* = 0.039); however, the frequency of brain metastasis at initial diagnosis was not significantly different between *RET*+ and *ALK*+ NSCLC (*RET*: 32% vs *ALK*: 25%; *p* = 0.592). The incidences of lung, pleural, lymphangitic, or pericardial spread were comparable across the three molecular subgroups. All three fusion cohorts had a high incidence of extrathoracic metastases (detected in 59%--77% of patients), including to the bone, without a significant difference ([Table 3](#cancers-12-00693-t003){ref-type="table"}). Sclerotic-type bone metastases were common in the three molecular subgroups (*RET*: 80% vs *ALK*: 68%, *p* = 0.703; vs *ROS1*: 56%; *p* = 0.399).

3. Discussion {#sec3-cancers-12-00693}
=============

*RET* fusions are a targetable oncogenic driver in NSCLC, with two promising *RET*-selective inhibitors now on the horizon \[[@B15-cancers-12-00693],[@B22-cancers-12-00693],[@B23-cancers-12-00693],[@B24-cancers-12-00693]\]. To our knowledge, this is the largest study to date to systematically assess the imaging features of the primary tumor and patterns of distant metastases in advanced *RET+* NSCLC, in comparison to *ALK*+ and *ROS1*+ NSCLC. Our findings revealed that the primary tumors in advanced *RET*+ NSCLC tended to be solid in density and not typically associated with air bronchograms, cavitation, or calcification, similar to *ALK*+ and *ROS1*+ NSCLC. However, primary *RET*+ tumors were more likely to be peripheral rather than central in location. All three fusion subgroups were relatively frequently associated with pleural metastases and lymphangitic carcinomatosis and extrathoracic metastases, brain, and bone metastases, at initial presentation. When bone metastases were present, these tended to be sclerotic rather than lytic.

These findings add to the emerging literature evaluating radiologic features and metastatic patterns in tumors harboring specific oncogenic drivers. Several prior studies have reported that certain imaging features may suggest the presence of gene alterations in NSCLC, and that the presence of these radiologic features may therefore help with triaging patients for expedited or repeat molecular testing when clinically warranted \[[@B26-cancers-12-00693],[@B27-cancers-12-00693],[@B28-cancers-12-00693],[@B36-cancers-12-00693],[@B37-cancers-12-00693],[@B38-cancers-12-00693],[@B39-cancers-12-00693],[@B40-cancers-12-00693]\]. The available data on the imaging features of *RET+* NSCLC are more limited \[[@B31-cancers-12-00693],[@B38-cancers-12-00693],[@B39-cancers-12-00693]\]. While molecular testing of the more common targetable alterations, including *EGFR* mutations and *ALK* fusions, in advanced NSCLC is recommended by national and international lung cancer guidelines, testing for *RET* fusions has not yet been as widely adopted, at least partly owing to the dearth of selective *RET* inhibitors until recently \[[@B41-cancers-12-00693],[@B42-cancers-12-00693]\]. In select patients with clinical and imaging features suggestive of *RET*+ NSCLC---and in the absence of other well-validated targets such as *EGFR* or *BRAF* mutations, *ALK* or *ROS1* fusions on initial genotyping---it would be prudent to consider further testing for *RET* fusions so as to potentially expand effective treatment options for these patients.

In our cohort, the *RET*+ NSCLC primary tumors were mostly solid without associated air bronchograms, cavitation, or calcification ([Figure 1](#cancers-12-00693-f001){ref-type="fig"}). These primary tumor imaging features are not significantly different compared to the *ALK*+ and *ROS1*+ NSCLC tumors included in our cohort ([Table 2](#cancers-12-00693-t002){ref-type="table"}) or compared to prior reports on *ALK* or *ROS1*+ tumors \[[@B26-cancers-12-00693],[@B31-cancers-12-00693],[@B37-cancers-12-00693],[@B38-cancers-12-00693],[@B43-cancers-12-00693]\]. In this study, the primary *RET*+ tumors were more commonly peripheral rather than central in location, concordant with available literature \[[@B38-cancers-12-00693],[@B39-cancers-12-00693]\]. Plodkowski et al. similarly reported that *RET+* NSCLC had an increased tendency for peripheral location \[[@B38-cancers-12-00693]\]. However, their main comparison subgroup included *EGFR*-mutant NSCLC, rather than *ALK*+ NSCLC. Comparison with *ALK*+ NSCLC may be of added utility given the significant overlap in the clinical features of the two fusion driver subgroups \[[@B8-cancers-12-00693],[@B18-cancers-12-00693],[@B44-cancers-12-00693],[@B45-cancers-12-00693]\]. An additional study by Saiki et al. also suggested that most primary tumors in *RET+* NSCLC were peripherally located \[[@B39-cancers-12-00693]\]. The peripheral propensity of *RET*+ tumors may have potential diagnostic or therapeutic implications, such as approaches to tissue sampling, surgery, or the delivery of radiation \[[@B46-cancers-12-00693],[@B47-cancers-12-00693],[@B48-cancers-12-00693]\].

The frequency of brain metastases at initial diagnosis of advanced *RET*+ NSCLC observed in our study is noteworthy. Approximately a third (32%) of patients with *RET*+ NSCLC were found to have baseline brain metastases at initial diagnosis, which is comparable to the incidence detected in *ALK*+ NSCLC and higher than that in *ROS1*+ NSCLC ([Table 3](#cancers-12-00693-t003){ref-type="table"}). Previous studies have suggested that *ALK*+ NSCLC may be associated with a higher frequency of brain metastases at initial diagnosis and cumulatively \[[@B34-cancers-12-00693]\], and that *RET*+ NSCLC may be associated with a significant cumulative incidence of brain metastases during patients' disease course (at a level intermediate between that observed in *ALK*+ NSCLC and *ROS1*+ NSCLC) \[[@B35-cancers-12-00693]\]. The significant incidence of brain metastases in *RET*+ disease underscores the importance of developing RET-targeted therapeutic agents with robust central nervous system (CNS) activity. In this regard, both *RET*-selective TKIs, BLU-667 and LOXO-292 have demonstrated preliminary encouraging CNS activity in patients with advanced *RET*+ NSCLC and baseline brain metastases \[[@B19-cancers-12-00693],[@B23-cancers-12-00693],[@B25-cancers-12-00693],[@B35-cancers-12-00693]\].

The patients with *RET+* NSCLC in our cohort, otherwise, shared similar patterns of metastases to those with *ALK+* or *ROS1+* NSCLC, including high frequencies of pleural and bone metastases and lymphangitic carcinomatosis ([Table 3](#cancers-12-00693-t003){ref-type="table"}; [Figure 1](#cancers-12-00693-f001){ref-type="fig"}). Notably, the osseous metastases in all three fusion subgroups tended to be predominantly sclerotic, rather than lytic as has previously been associated with NSCLC ([Figure 1](#cancers-12-00693-f001){ref-type="fig"}) \[[@B49-cancers-12-00693],[@B50-cancers-12-00693]\]. To our knowledge, no prior studies have reported the propensity for sclerotic bone metastases in *RET*+. Notably, a similar predilection for sclerotic bone metastases has been reported in *ALK*+, or *ROS1+* NSCLC \[[@B29-cancers-12-00693],[@B40-cancers-12-00693]\]. The molecular mechanisms underlying the propensity for the development of sclerotic osseous metastases in these fusion-driven lung cancers remain to be studied.

Our study had several limitations. Although this is the largest study to date to assess the imaging features and metastatic patterns in *RET+* NSCLC, our cohort is still relatively small due to the rarity of *RET* alterations in NSCLC overall. Thus, the statistical power was limited in determining significant differences among the three molecular subgroups. The moderate sample sizes also precluded multivariable analysis adjusting for confounding factors to obtain stable and precise estimates of any effect size. The data were collected retrospectively from a single institution, predisposing to selection and referral bias and potentially limiting their generalizability to larger populations. Additionally, the study did not evaluate for differences between *RET*+ NSCLC and oncogenic subsets of NSCLC other than *ALK*+ or *ROS1*+ NSCLC (such as *EGFR*-mutant NSCLC, *BRAF*-mutant NSCLC, etc.). These comparator cohorts were chosen because *ALK* and *ROS1* fusions represent two well-validated fusion targets in NSCLC. Despite these limitations, our findings add to the growing understanding of the clinical and radiologic features of *RET+* NSCLC. In select patients with clinical and imaging features suggestive of *RET*+ NSCLC, and negative testing for *EGFR*, *BRAF*, *ALK*, or *ROS1* alterations, further molecular testing for *RET* fusions may be advisable.

4. Materials and Methods {#sec4-cancers-12-00693}
========================

4.1. Patient Identification {#sec4dot1-cancers-12-00693}
---------------------------

This retrospective study was performed under an institutional review board-approved protocol (Partners Human Research Protocol \#: 2019P000198). Patients were eligible if they fulfilled the following criteria: (1) had the diagnosis of advanced/metastatic NSCLC with a *RET, ALK,* or *ROS1* fusion confirmed by locally accepted testing at the time of presentation (e.g., fluorescent in situ hybridization, polymerase chain reaction, next-generation sequencing, and/or immunohistochemistry (for *ALK*)); (2) were seen in the thoracic oncology clinic of Massachusetts General Hospital between January 2014 and December 2018; and (3) had pre-treatment imaging performed at our institution, or at another facility, with the examination uploaded into the picture archiving and communication system (PACS) for radiologist review. The testing method used to detect the driver mutations varied depending on when the patient presented. Clinicopathologic data were extracted from the electronic medical records, including patient age, sex, race, smoking history, tumor histology, and stage of disease at initial diagnosis per the American Joint Committee on Cancer TNM Staging, 7th edition.

4.2. Imaging Review and Analysis {#sec4dot2-cancers-12-00693}
--------------------------------

Baseline imaging data obtained at diagnosis prior to the initiation of therapy (e.g., surgery, radiation, or systemic therapy) were selected and reviewed on the institutional PACS (AGFA Impax 6, Mortsel, Belgium). Required imaging studies included, at minimum, computed tomography (CT) scans of the chest, abdomen, and pelvis with or without concurrent fluorodeoxyglucose (FDG)-positron emission tomography (PET), and CT and/or magnetic resonance imaging (MRI) of the brain. Radiologic findings were determined by consensus between two radiologists (S.R.D. and D.P.M.).

When a primary tumor was identifiable, CT features of the primary tumor were analyzed with regard to its size, lobe, axial location (i.e., central versus peripheral), density (i.e., solid versus subsolid), and the presence or absence of cavitation, air bronchograms, or calcification. Images were also assessed for lymphadenopathy and thickening of the interstitium suggestive of lymphangitic carcinomatosis. A lymph node was considered malignant if it measured greater than 1 cm in its short axis and/or had increased FDG uptake on 18-FDG PET imaging. Malignant lymph nodes were recorded as ipsilateral or contralateral, and as hilar, mediastinal, supraclavicular, or distant (e.g., cervical, axillary, intra-abdominal, etc.). Other sites examined for evidence of metastases included the lungs, pleura, pericardium, liver, adrenal glands, other visceral organs (e.g., spleen, kidney), brains, bones, and subcutaneous soft tissues. Bone metastases were additionally classified as predominantly lytic versus predominantly blastic or sclerotic.

4.3. Statistical Analysis {#sec4dot3-cancers-12-00693}
-------------------------

To preserve power given modest sample sizes, we performed pairwise comparisons between patients with *RET*+ NSCLC and patients with *ALK*+ or *ROS1*+ NSCLC. Fisher's exact test was used to compare clinicopathologic characteristics of patients and imaging features of the primary tumor between molecular subgroups as well as distribution of metastatic sites among patients with advanced NSCLC. Wilcoxon rank-sum test was used to analyze the age distribution at initial diagnosis. Data analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC, USA), and *p*-values were reported for two-sided tests.

5. Conclusions {#sec5-cancers-12-00693}
==============

*RET*+ NSCLC shares several radiologic features with *ALK*+ and *ROS1+* NSCLC, including solid density of the primary tumor and high frequencies of lymphangitic carcinomatosis and pleural, brain, and bone metastases. When bone metastases are present, these are often sclerotic in nature. These imaging features may suggest the presence of *RET* fusions and help triage those patients who may benefit from further molecular genotyping.
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![Representative imaging features in a 62-year-old female with *RET*+ NSCLC. Pretreatment CT shows a solid nodule in the peripheral right upper lobe (**A**, arrow) and associated septal and peribronchial thickening consistent with lymphangitic carcinomatosis (**A**,**B**, arrowheads). There was also an associated malignant pleural effusion (**C**, arrow), mediastinal and hilar lymphadenopathy (**C**, arrowheads)**,** and a sclerotic osseous metastasis of the first lumbar vertebral body (**D**, arrow).](cancers-12-00693-g001){#cancers-12-00693-f001}

cancers-12-00693-t001_Table 1

###### 

Clinicopathologic features of patients with *RET*, *ALK*, and *ROS1* fusion-positive NSCLC.

  Clinical Feature      *RET*      *ALK*       *ROS1*      *RET* vs. *ALK*   *RET* vs. *ROS1*
  --------------------- ---------- ----------- ----------- ----------------- ------------------
  **Age**                                                                    
  Median                64         51          54          *\<0.0001*        *0.042*
  Range                 (42--83)   (19--75)    (23--89)                      
  **Sex**                                                                    
  Female                14 (44%)   66 (57%)    49 (73%)    0.230             *0.007*
  Male                  18 (56%)   50 (43%)    18 (27%)                      
  **Race**                                                                   
  Caucasian             26 (81%)   90 (78%)    49 (73%)    0.868             0.378
  Asian                 5 (16%)    17 (15%)    10 (15%)                      
  Other                 1 (3%)     9 (8%)      8 (12%)                       
  **Smoking history**                                                        
  Never                 23 (72%)   87 (75%)    45 (67%)    0.820             0.817
  Prior/current         9 (28%)    29 (25%)    22 (33%)                      
  **Tumor histology**                                                        
  Adenocarcinoma        28 (88%)   108 (93%)   67 (100%)   *0.025*           *0.010*
  Neuroendocrine        4 (12%)    2 (2%)      0                             
  Other                 0          6 (5%)      0                             
  **Stage**                                                                  
  I-II                  8 (25%)    7 (6%)      5 (7%)      *0.0044*          *0.023*
  III                   2 (6%)     22 (19%)    13 (19%)                      
  IV                    22 (69%)   87 (75%)    49 (73%)                      

Statistically significant *p*-values are highlighted.

cancers-12-00693-t002_Table 2

###### 

Imaging features of the primary tumor in patients with *RET*, *ALK*, or *ROS1* fusion-positive NSCLC.

  Imaging Feature     *RET*      *ALK*       *ROS1*      *RET* vs. *ALK*   *RET* vs. *ROS1*
  ------------------- ---------- ----------- ----------- ----------------- ------------------
  Tumor size (mm)                                                          
   Median             32         41          33          0.258             0.836
   Range              (9--89)    (5--115)    (10--126)                     
   ≥3 cm              19 (59%)   80 (69%)    37 (55%)    0.396             0.829
  Density                                                                  
   Solid              30 (94%)   115 (99%)   64 (96%)    0.118             0.657
   Subsolid           2 (6%)     1 (1%)      3 (4%)                        
  Other features                                                           
   Air bronchograms   2 (6%)     7 (6%)      3 (4%)      1.000             0.657
   Cavitation         0          7 (6%)      2 (3%)      0.347             1.000
   Calcification      0          0           0                             
  Tumor location                                                           
   RUL                4 (12%)    28 (24%)    14 (21%)    0.249             0.477
   RML                6 (19%)    10 (9%)     10 (15%)                      
   RLL                8 (25%)    24 (21%)    19 (28%)                      
   LUL                8 (25%)    22 (19%)    8 (12%)                       
   LLL                6 (19%)    32 (28%)    16 (24%)                      
  Lobar level                                                              
   Lower              14 (44%)   56 (48%)    35 (52%)    0.693             0.521
   Upper              18 (56%)   60 (52%)    32 (48%)                      
  Laterality                                                               
   Left               14 (44%)   54 (47%)    24 (36%)    0.843             0.510
   Right              18 (56%)   62 (53%)    43 (64%)                      
  Axial location                                                           
   Central            10 (31%)   62 (53%)    43 (64%)    *0.029*           *0.003*
   Peripheral         22 (69%)   54 (47%)    24 (36%)                      

RUL = right upper lobe; RML = right middle lobe; RLL = right lower lobe; LUL = left upper lobe; LLL = left lower lobe. Statistically significant *p*-values are highlighted.

cancers-12-00693-t003_Table 3

###### 

Patterns of metastatic sites among patients with advanced *RET*, *ALK*, or *ROS1* fusion-positive NSCLC.

  Metastatic Site               *RET*      *ALK*      *ROS1*     *RET* vs. *ALK*   *RET* vs. *ROS1*
  ----------------------------- ---------- ---------- ---------- ----------------- ------------------
  **Intrathoracic**             14 (64%)   64 (74%)   41 (84%)   0.429             0.074
  Lung                          4 (18%)    18 (21%)   18 (37%)   1.000             0.167
  Pleural                       10 (45%)   35 (40%)   20 (41%)   0.809             0.797
  Lymphangitic carcinomatosis   6 (27%)    35 (40%)   21 (43%)   0.329             0.292
  Pericardium                   1 (5%)     2 (2%)     2 (4%)     0.495             1.000
  **Extrathoracic**             17 (77%)   65 (75%)   29 (59%)   1.000             0.183
  Bone                          10 (45%)   41 (47%)   16 (33%)   1.000             0.425
  Sclerotic metastasis          8 (80%)    28 (68%)   9 (56%)    0.703             0.399
  Liver                         3 (14%)    21 (24%)   10 (20%)   0.393             0.741
  Brain                         7 (32%)    22 (25%)   5 (10%)    0.592             *0.039*
  Distant lymph nodes           5 (23%)    17 (20%)   8 (16%)    0.769             0.524
  Adrenal                       4 (18%)    6 (7%)     7 (14%)    0.114             0.729
  Soft tissue                   1 (5%)     5 (6%)     1 (2%)     1.000             0.527
